Literature DB >> 7629790

New orally active serine protease inhibitors.

K Senokuchi1, H Nakai, Y Nakayama, Y Odagaki, K Sakaki, M Kato, T Maruyama, T Miyazaki, H Ito, K Kamiyasu.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7629790     DOI： 10.1021/jm00014a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  3 in total

1.  DOGS: reaction-driven de novo design of bioactive compounds.

Authors:  Markus Hartenfeller; Heiko Zettl; Miriam Walter; Matthias Rupp; Felix Reisen; Ewgenij Proschak; Sascha Weggen; Holger Stark; Gisbert Schneider
Journal:  PLoS Comput Biol       Date:  2012-02-16       Impact factor: 4.475

2.  An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.

Authors:  Jonathan H Shrimp; Stephen C Kales; Philip E Sanderson; Anton Simeonov; Min Shen; Matthew D Hall
Journal:  ACS Pharmacol Transl Sci       Date:  2020-09-07

3.  Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.

Authors:  Markus Hoffmann; Heike Hofmann-Winkler; Joan C Smith; Nadine Krüger; Lambert K Sørensen; Ole S Søgaard; Jørgen Bo Hasselstrøm; Michael Winkler; Tim Hempel; Lluís Raich; Simon Olsson; Takashi Yamazoe; Katsura Yamatsuta; Hirotaka Mizuno; Stephan Ludwig; Frank Noé; Jason M Sheltzer; Mads Kjolby; Stefan Pöhlmann
Journal:  bioRxiv       Date:  2020-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.